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Many patients with chronic obstructive airways disease (COAD) receive therapy by the inhaled route. This study 
was performed to assess whether patients with severe COAD could generate sufficient peak inspiratory flow (PIF) 
through Turbuhalera (Astra, Sodertalje) to operate it effectively. 
One hundred patients (45 men, 55 women, mean age 69.1 years) with COAD (mean (SD.) duration 17.7 (16.3) 
years) and peak expiratory flow (PEF) < 200 1 min - ’ or forced expiratory volume in 1 set (FEV,) I 1 litre were 
studied. A series of randomly assigned inspiratory and expiratory lung function tests were contiguously performed, 
using portable spirometers, within 48 h of a screening visit. An empty Turbuhaler@ was used in the study. The 
patients’ normal medication was not restricted. Sixty-six patients were previous smokers, eight occasional smokers, 
19 habitual smokers and seven had never smoked. 
Mean (SD) FEV, was 0.7 (0.2) 1 and mean PEF was 182 (68) 1 min- ‘. All patients were able to generate PIF 
through Turbuhalera (PIF-T) of 28 1 min ~ 1 (mean 53; range 28-78 1 min ~ ‘). Eighty-three patients generated PIF-T 
of 240 1 min- I. PIF-T correlated with PIF without Turbuhalera (v=O.35), PEF (r=0.3), FEV, (r=0.2) and forced 
vital capacity (FVC) (r=0.23) although the relationships were too weak to be used to predict PIF-T. 
The results suggest that patients with severely limited lung function caused by COAD can operate Turbuhaler@ 
effectively. 
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Introduction 
Bronchodilator therapy by the inhaled route is now 
established as preferable to oral therapy in both chronic 
obstructive airways disease (COAD) and asthma. Also, 
anticholinergic bronchodilators are available only for inha- 
lation and are often used in the treatment of COAD as well 
as inhaled &adrenoreceptor agonists such as salbutamol 
and terbutaline. Many patients with COAD are elderly and 
are often unable to achieve coordination of inspiration and 
actuation when using a conventional pressurized metered 
dose inhaler (1). Turbuhaler@ (Astra, Sodertalje) is an 
inspiratory flow driven dry powder device which can be 
used in preference to the pMD1 (2-4) and does not contain 
lubricants or propellants, which in themselves can cause 
bronchoconstriction (5-7). An inspiratory flow rate of 
228 lmin- ’ through the Turbuhaler@ should be generated 
to operate it effectively (8). This can be achieved by all 
asthmatic adults (9), children aged 6 years or more (8) and 
98% of asthmatic patients with a severe exacerbation 
requiring hospitalization (10). 
Received 26 October 1998 and accepted 9 February 1999. 
Correspondence should be addressed to: Dr G. K. Crompton, 
Respiratory Medicine Unit, Western General Hospital, Edinburgh 
EH4 2)cU, U.K. Fax: +44(O) 131 343 3989. 
0954-6111/99/050342+03 $12.00/O 
This study was designed to assess whether patients with 
COAD can generate sufficient inspiratory flow to use 
Turbuhalera effectively. A second aim was to assess if other 
lung function variables could be used to predict peak 
inspiratory flow through TurbuhaleP (PIF-T). 
Methods 
The study was approved by the local ethics committee and 
conducted in accordance with the guidelines of the declar- 
ation of Helsinki. All patients gave written informed 
consent. 
One hundred and ten patients, aged 2 18 years, with a 
confirmed diagnosis of COAD were screened either in 
hospital or in the outpatient clinic. One hundred patients 
(45 men, 55 women, mean age 69.1 years) fulfilled the 
selection criteria [peak expiratory flow (PEF) 1200 1 
min-’ or forced expiratory volume in 1 set (FEV,) 
I 1 litre]. Thirty-seven were inpatients following an acute 
exacerbation of COAD. Sixty-six were previous smokers, 
eight occasional smokers, 19 habitual smokers and seven 
had never smoked. Mean (SD) duration of COAD was 17.7 
(16.3) years. 
Within 48 h of screening, the patients underwent a series 
of inspiratory and expiratory lung function measurements. 
The order of these tests (inspiratory vs. expiratory) was 
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randomly assigned with a pause of 10 min between assess- 
ments. The tests were performed either in hospital or in the 
patient’s home under the supervision of one of the authors 
(M.H.D.) using portable spirometers (Vitalograph 
Compact, Vitalograph Ltd., Buckingham, U.K.). A maxi- 
mal forced expiration was performed, from which the 
FEV,, forced vital capacity (FVC) and forced expiratory 
flow between 25% and 75% of FVC (FEF,,-,,) were 
derived. PEF was measured using a Vitalograph peak 
expiratory flow meter with absolute scale. A maximal 
forced expiration immediately followed by a maximal 
forced inspiration was performed to measure the peak 
inspiratory flow without Turbuhalerm (PIF) from the 
inspiratory limb of the flow volume loop. Peak inspiratory 
flow through empty Turbuhalerm (PIF-T) was then 
measured during a maximal forced inspiration using 
another spirometer attached to an adaptor in which an 
empty Turbuhaler@ was mounted. Noseclips were used for 
both inspiratory measurements and for all variables the best 
of three measurements was used for analysis. Relationships 
between variables were analysed statistically using Pearson 
product moment correlation tests. 
Results 
Mean (SD) expiratory flow values were: FEV,, 0.70 (0.21) 1; 
FVC 1.74 (0.56) 1; PEF 182 (68) 1 min- ‘. Mean (SD) PIF 
was 107 (52) 1 min- i and PIF-T was 53 (12) 1 min - ‘. All 
patients were able to generate a PIF of at least 28 1 min - ’ 
through the Turbuhalerm, 83 generated PIF-T of 240 1 
mini and 32 generated PIF-T of 2 60 1 min - ‘. The 
distribution of PIF-T is shown in Fig. 1. Weak but signifi- 
cant (PcO.05) correlations were found between PIF and 
FEV, (r=0.33), PIF and FVC (v=O.34), PIF-T and PEF 
(r=0,30) and PIF-T and PIF (r=0.35). No correlation was 
found between FEFZZmT5 and PIF or PIF-T. 
Discussion 
Turbuhalerm is a high-resistance inspiratory flow driven 
device. As such, there may have been concern that COAD 
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patients with diminished lung function may have been 
unable to operate Turbuhaler@ effectively. This study was 
carried out to address this concern. 
From the results it is apparent that patients with COAD 
selected for the study were all able to generate a PIF-T of 
greater than 28 1 min - ‘. This is sufficient to operate 
Turbuhalera effectively and receive a therapeutically active 
amount of bronchodilator drug to the airways. Significant 
correlations were found between inspiratory and expiratory 
flow rates, but these were too weak to allow PIF or PIF-T 
to be predicted from either PEF or FEV,. The correlation 
coefficients found for PIF and expiratory flow rates were 
lower than those obtained by Brown et al. (10) in 99 adult 
patients presenting to hospital with acute exacerbations of 
asthma and by Engel et al. in outpatients with asthma (11). 
The latter study examined 101 adults with less severe 
airways obstruction (mean FEV, =2.4 1) and similarly 
found a weak relationship between expiratory flow rates 
and PIF. This study also found that FEV, was less well 
correlated with PIF-T than with PIF. In contrast to Engel’s 
study, we found that there was slightly more correlation 
between PEF and PIF-T than with PIF. However, the 
overall findings are the same and confirm that both expira- 
tory lung function measurements and standardly measured 
PIF cannot predict PIF-T through TurbuhaleP. 
In summary, this study demonstrates that patients with 
COAD with low expiratory flow can use Turbuhalera 
effectively. These findings are in line with those for patients 
with acute and moderate to severe asthma. 
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